AnaptysBio (NASDAQ:ANAB) Lifted to Neutral at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of AnaptysBio (NASDAQ:ANAB – Get Rating) from an underweight rating to a neutral rating in a research note published on Monday, The Fly reports. JPMorgan Chase & Co. currently has $30.00 price objective on the biotechnology company’s stock, down from their previous price objective of $31.00.

Other analysts also recently issued research reports about the stock. StockNews.com assumed coverage on shares of AnaptysBio in a research note on Thursday, May 18th. They set a hold rating for the company. Guggenheim boosted their price objective on shares of AnaptysBio from $44.00 to $45.00 in a research note on Friday, May 12th. Finally, TD Cowen initiated coverage on shares of AnaptysBio in a research note on Thursday, May 18th. They issued an outperform rating for the company. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of Hold and a consensus price target of $34.67.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $18.64 on Monday. The company has a market cap of $493.77 million, a P/E ratio of -3.85 and a beta of -0.16. AnaptysBio has a 1 year low of $18.03 and a 1 year high of $32.44. The firm has a 50-day simple moving average of $21.08 and a two-hundred day simple moving average of $24.68.

AnaptysBio (NASDAQ:ANAB – Get Rating) last announced its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.54). AnaptysBio had a negative return on equity of 52.83% and a negative net margin of 1,278.87%. The firm had revenue of $1.37 million during the quarter, compared to the consensus estimate of $4.02 million. As a group, equities research analysts expect that AnaptysBio will post -6.42 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jennison Associates LLC acquired a new position in AnaptysBio during the fourth quarter valued at $614,000. Federated Hermes Inc. raised its position in shares of AnaptysBio by 3.0% in the third quarter. Federated Hermes Inc. now owns 2,372,923 shares of the biotechnology company’s stock worth $60,533,000 after acquiring an additional 68,826 shares during the period. New York State Common Retirement Fund raised its position in shares of AnaptysBio by 25.6% in the fourth quarter. New York State Common Retirement Fund now owns 17,142 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 3,489 shares during the period. Barclays PLC raised its position in shares of AnaptysBio by 4,691.1% in the third quarter. Barclays PLC now owns 48,773 shares of the biotechnology company’s stock worth $1,244,000 after acquiring an additional 47,755 shares during the period. Finally, US Bancorp DE raised its position in shares of AnaptysBio by 44.4% in the third quarter. US Bancorp DE now owns 1,538 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 473 shares during the period.

About AnaptysBio

(Get Rating)

AnaptysBio, Inc is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro.